News in brief

Catalent clinical supply plant opens its doors in China

Catalent clinical supply plant opens its doors in China

Catalent has cut the ribbon on its Clinical Supply facility in China just months after construction began.

Back in February, this publication reported news of Catalent’s expansion into China with the acquisition of a softgel firm and a joint venture with local CRO ShangPharma Corporation to provide end-to-end solutions for clinical trials from a new facility in Shanghai.

Last week, the latter was completed less than nine months after construction began and the 31,000 sq ft clinical trial site opened its doors.

China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” saidScott Houlton, President of Development and Clinical Services at Catalent, at a ceremony last week.

I’m excited to see this strategy implemented and the new site open for business. It is a great addition to Catalent’s global clinical supply network and will help to better serve our customers increasing need for clinical trials in Asia.”

Initially, the site would employ more than twenty staff by the end of this year, spokesman Chris Halling told this publication back in February, but as the Clinical Supply activity in China and Asia grows, so too will the workforce.

Related News

Catalent's $100m IPO could be five times that, says investment firm

Catalent looks to go public with $100m IPO

Kansas City, Missouri - Catalent expanding and adding jobs at ex-Aptuit facility

Catalent to increase workforce by two thirds at Kansas City plant

Adopt highest GMP/GDP standards for Asian clinical trials, says Almac

Adopt highest GMP/GDP standards for Asian clinical trials, says Almac

Catalent Focuses on Clinical Services in One of Two Chinese Ventures

Catalent Focuses on Clinical Services in One of Two Chinese Ventures

Catalent purchases Brazilian softgel firm Relthy Labs

Catalent's Brazilian acquisition supports global softgel strategy

Capsule talks softegl tech at CPhI Frankfurt

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent invests $20m

Catalent inhales $20m investment

Catalent Completes Chinese Softgel Acquisition

Catalent Completes Chinese Softgel Acquisition

Catalent Quadruples Biologics Services with Opening of New plant

Catalent Quadruples Biologics Services with Opening of New plant

Moving on up? People on the move

People: Appointments for PPD, Catalent and Columbia

Related Products

See more related products